Featured
-
-
Article
| Open AccessAn atlas of epithelial cell states and plasticity in lung adenocarcinoma
Analyses of single epithelial cells from early-stage lung adenocarcinoma and normal lung identifies a population of intermediate cells that may have an increased likelihood of transforming to tumour cells after injury such as tobacco exposure.
- Guangchun Han
- , Ansam Sinjab
- & Humam Kadara
-
Article |
p53 governs an AT1 differentiation programme in lung cancer suppression
p53 is shown to have a pivotal role in the differentiation of alveolar type 1 cells in cancer and alveolar repair after injury, and loss of this governance can promote diseases such as lung adenocarcinoma.
- Alyssa M. Kaiser
- , Alberto Gatto
- & Laura D. Attardi
-
Article |
KRAS(G12D) drives lepidic adenocarcinoma through stem-cell reprogramming
A study identifies the AT1 cell as a cell of origin for lung adenocarcinoma, and demonstrates that expression of oncogenic KRAS in differentiated AT1 cells reprograms them back into AT2 stem cells that generate indolent lepidic tumours.
- Nicholas H. Juul
- , Jung-Ki Yoon
- & Tushar J. Desai
-
Article |
Therapy-induced APOBEC3A drives evolution of persistent cancer cells
Induction of APOBEC3A in response to targeted therapies drives evolution of drug-tolerant persister cells, suggesting that its suppression may represent a potential therapeutic strategy in the prevention of acquired resistance to lung cancer targeted therapy.
- Hideko Isozaki
- , Ramin Sakhtemani
- & Aaron N. Hata
-
Article |
Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA
Measurements of subclonal expansion of ctDNA in the plasma before surgery may enable the prediction of future metastatic subclones, offering the possibility for early intervention in patients with non-small-cell lung cancer.
- Christopher Abbosh
- , Alexander M. Frankell
- & Charles Swanton
-
Article
| Open AccessGenomic–transcriptomic evolution in lung cancer and metastasis
Computational and machine-learning approaches that integrate genomic and transcriptomic variation from paired primary and metastatic non-small cell lung cancer samples from the TRACERx cohort reveal the role of transcriptional events in tumour evolution.
- Carlos Martínez-Ruiz
- , James R. M. Black
- & Nicholas McGranahan
-
Article
| Open AccessThe evolution of non-small cell lung cancer metastases in TRACERx
A longitudinal evolutionary analysis of 126 lung cancer patients with metastatic disease reveals the timing of metastatic divergence, modes of dissemination and the genomic events subject to selection during the metastatic transition.
- Maise Al Bakir
- , Ariana Huebner
- & Charles Swanton
-
Article
| Open AccessAntibodies against endogenous retroviruses promote lung cancer immunotherapy
In lung adenocarcinoma, antibodies against endogenous retroviruses promote anti-tumour activity, and expression of endogenous retroviruses can predict outcomes of immunotherapy.
- Kevin W. Ng
- , Jesse Boumelha
- & George Kassiotis
-
Article |
Lung adenocarcinoma promotion by air pollutants
Combination of epidemiology, preclinical models and ultradeep DNA profiling of clinical cohorts unpicks the inflammatory mechanism by which air pollution promotes lung cancer
- William Hill
- , Emilia L. Lim
- & Charles Swanton
-
Article
| Open AccessSpatial mapping of mitochondrial networks and bioenergetics in lung cancer
A study describing an approach that combines imaging and profiling techniques to structurally and functionally analyse lung cancer in vivo, revealing heterogeneous mitochondrial networks and an association between bioenergetic phenotypes and mitochondrial organization and function.
- Mingqi Han
- , Eric A. Bushong
- & David B. Shackelford
-
Article
| Open AccessSingle-cell spatial landscapes of the lung tumour immune microenvironment
Using imaging mass cytometry, the tumour and immunological spatial landscapes of 416 lung adenocarcinomas are characterized, which, when combined with deep learning, can predict clinical outcomes with high accuracy.
- Mark Sorin
- , Morteza Rezanejad
- & Logan A. Walsh
-
Article |
The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer
Whole-transcriptome sequencing of a subset of 75 non-small-cell lung cancer specimens in a multi-institutional genome screening study identified a fusion of the CLIP1 and LTK genes with transformational potential due to constitutive LTK kinase activity.
- Hiroki Izumi
- , Shingo Matsumoto
- & Koichi Goto
-
Article |
Diverse alterations associated with resistance to KRAS(G12C) inhibition
Multiple treatment-emergent alterations appear in patients with advanced-stage cancer who were treated with a KRAS inhibitor.
- Yulei Zhao
- , Yonina R. Murciano-Goroff
- & Piro Lito
-
Article
| Open AccessStructure-based classification predicts drug response in EGFR-mutant NSCLC
Structural classification of mutations in the epidermal growth factor receptor causing non-small cell lung cancer is a better predictor of patient outcomes following drug treatment than traditional exon-based classification.
- Jacqulyne P. Robichaux
- , Xiuning Le
- & John V. Heymach
-
Article |
Elevated NSD3 histone methylation activity drives squamous cell lung cancer
The histone H3K36 methyltransferase NSD3, which is associated with the common 8p11–12 chromosomal amplification, is an oncogenic driver in lung squamous cell carcinoma.
- Gang Yuan
- , Natasha M. Flores
- & Or Gozani
-
Article |
The National Lung Matrix Trial of personalized therapy in lung cancer
Current outcomes are reported from the ongoing National Lung Matrix Trial, an umbrella trial for the treatment of non-small-cell lung cancer in which patients are triaged according to their tumour genotype and matched with targeted therapeutic agents.
- Gary Middleton
- , Peter Fletcher
- & Lucinda Billingham
-
Matters Arising |
Reply to: In vivo quantification of mitochondrial membrane potential
- Milica Momcilovic
- , Orian Shirihai
- & David B. Shackelford
-
Article |
Integrating genomic features for non-invasive early lung cancer detection
Circulating tumour DNA in blood is analysed to identify genomic features that distinguish early-stage lung cancer patients from risk-matched controls, and these are integrated into a machine-learning method for blood-based lung cancer screening.
- Jacob J. Chabon
- , Emily G. Hamilton
- & Maximilian Diehn
-
Article |
Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
Populations of KRAS(G12C)-mutant cancer cells can rapidly bypass the effects of treatment with KRAS(G12C) inhibitors because a subset of cells escapes drug-induced quiescence by producing new KRAS(G12C) that is maintained in its active, drug-insensitive state.
- Jenny Y. Xue
- , Yulei Zhao
- & Piro Lito
-
Article |
In vivo imaging of mitochondrial membrane potential in non-small-cell lung cancer
A positron emission tomography imaging tracer is developed to image mitochondrial function in vivo, and application of this tracer to a mouse model of lung cancer identifies distinct functional mitochondrial heterogeneity between tumour cells.
- Milica Momcilovic
- , Anthony Jones
- & David B. Shackelford
-
Letter |
RB constrains lineage fidelity and multiple stages of tumour progression and metastasis
Loss of RB promotes both malignant progression and the development of metastatic disease; however, whereas reactivation of the RB pathway can revert metastatic tumour cell states to non-metastatic cell states, malignant cell proliferation is supported by MAPK–CDK2-dependent suppression of RB.
- David M. Walter
- , Travis J. Yates
- & David M. Feldser
-
Article |
Neoantigen-directed immune escape in lung cancer evolution
RNA sequencing data and tumour pathology observations of non-small-cell lung cancers indicate that the immune cell microenvironment exerts strong evolutionary selection pressures that shape the immune-evasion capacity of tumours.
- Rachel Rosenthal
- , Elizabeth Larose Cadieux
- & Andrew Kidd
-
Review Article |
The biology and management of non-small cell lung cancer
- Roy S. Herbst
- , Daniel Morgensztern
- & Chris Boshoff
-
Letter |
A Braf kinase-inactive mutant induces lung adenocarcinoma
Kinase-inactive Braf mutants can initiate the development of lung adenocarcinoma in mice; co-expression of activated Kras enhances tumour initiation and progression, and wild-type Braf is required to sustain tumorigenesis.
- Patricia Nieto
- , Chiara Ambrogio
- & David Santamaría
-
Letter |
A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma
A subset of Kras and p53 mutant cancer cells acts as a Wnt-producing niche for another cancer cell subset, and porcupine inhibition disrupts Wnt secretion in this niche, thereby suppressing proliferative potential and leading to therapeutic benefit.
- Tuomas Tammela
- , Francisco J. Sanchez-Rivera
- & Tyler Jacks
-
Article |
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
Circulating tumour DNA profiling in early-stage non-small-cell lung cancer can be used to track single-nucleotide variants in plasma to predict lung cancer relapse and identify tumour subclones involved in the metastatic process.
- Christopher Abbosh
- , Nicolai J. Birkbak
- & Charles Swanton
-
Letter |
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
An allosteric inhibitor, EAI045, is reported that is selective for certain drug-resistant EGFR mutants, but spares the wild-type receptor; combination therapy of EAI045 with EGFR-dimerization-blocking antibodies is effective in mouse models of lung cancer driven by mutant versions of EGFR that are resistant to all previously developed inhibitors.
- Yong Jia
- , Cai-Hong Yun
- & Michael J. Eck
-
Letter |
Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities
Mutant Kras lung tumours are not a single disease but comprise two classes of tumours with distinct metabolic profiles, prognosis and therapeutic susceptibility, which can be discriminated by their relative mutant Kras allelic content.
- Emma M. Kerr
- , Edoardo Gaude
- & Carla P. Martins
-
Letter |
The mutational landscapes of genetic and chemical models of Kras-driven lung cancer
Whole-exome sequencing is used to compare the mutational landscape of adenomas from three mouse models of non-small-cell lung cancer, induced either by exposure to carcinogens or by genetic mutation of Kras; the results reveal that the two types of tumour have different mutational profiles and adopt different routes to tumour development.
- Peter M. K. Westcott
- , Kyle D. Halliwill
- & Allan Balmain
-
Letter |
Rapid modelling of cooperating genetic events in cancer through somatic genome editing
The CRISPR/Cas system has been used in mice for genome editing to introduce genetic alterations found in human lung tumours, and these genome modifications resulted in mouse lung tumours showing different histopathologies depending on the genes altered; the CRISPR/Cas system offers improved and faster ways to create animal models of human diseases such as cancer.
- Francisco J. Sánchez-Rivera
- , Thales Papagiannakopoulos
- & Tyler Jacks
-
Letter |
HMGA2 functions as a competing endogenous RNA to promote lung cancer progression
HMGA2 promotes lung cancer progression in mice and humans; in mouse and human lung cancer cells, HMGA2 competes with mRNAs like TGFBR3 for the let-7 microRNA family, and in human non-small-cell lung cancer tissue, expression levels of HMGA2 and TGFBR3 are correlated, suggesting that HMGA2 functions both as a protein-coding gene and as a non-coding RNA.
- Madhu S. Kumar
- , Elena Armenteros-Monterroso
- & Julian Downward
-
News & Views |
Clinical trials unite mice and humans
Anticancer 'co-clinical' trials, in which mice carrying known mutations are treated in parallel with patients enrolled in a simultaneous clinical study, could help to improve therapeutic outcome. See Letter p.613
- Leisa Johnson
-
Letter |
Selective activation of p53-mediated tumour suppression in high-grade tumours
p53 is an important tumour suppressor gene. Two papers now show in a Kras-driven lung cancer model that p53-mediated tumour suppression is only engaged late during tumour progression, when the Kras oncogenic signal reaches a threshold sufficient to activate the ARF–p53 pathway. Therefore, p53 re-expression in p53-deficient lung tumours does not restrict early stages of tumorigenesis, but induces tumour regression of more aggressive tumours.
- Melissa R. Junttila
- , Anthony N. Karnezis
- & Carla P. Martins